What does MEUDON PHARMA do?

MEUDON PHARMA is a pharmacy in Sint-Lambrechts-Woluwe. Private Limited, started on 9 September 2015, 1 establishment.

What is the address of MEUDON PHARMA?

The registered office of MEUDON PHARMA is located at Georges Henrilaan 180, 1200 Sint-Lambrechts-Woluwe.

Is MEUDON PHARMA still active?

Yes. According to the CBE (2 November 2026) MEUDON PHARMA is active, legal situation “Normale toestand”, started on 9 September 2015.

Is MEUDON PHARMA registered on Peppol?

Yes, MEUDON PHARMA is registered on the Peppol network with ID 0208:0636880026.

What is the enterprise number of MEUDON PHARMA?

The enterprise number of MEUDON PHARMA is BE0636880026.

When was MEUDON PHARMA founded?

MEUDON PHARMA was founded on 9 September 2015.

Who are the directors of MEUDON PHARMA?

According to the 2025 annual accounts, the directors of MEUDON PHARMA are: Benoît MOUSSET, Catherine BARVAIS.

Is MEUDON PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 September 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 1 events from the Belgian Official Gazette processed.

How much profit did MEUDON PHARMA make in 2025?

MEUDON PHARMA posted a profit after taxes of € 5,593 in financial year 2025.

What is the revenue of MEUDON PHARMA?

As a small company, MEUDON PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 282,475.

How much does an employee at MEUDON PHARMA earn?

The average wage cost per full-time employee at MEUDON PHARMA was € 59,300 in 2025: staff costs of € 160,235 for 2.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does MEUDON PHARMA have?

According to the 2025 annual accounts, MEUDON PHARMA has 2.7 full-time equivalents (FTE).

MEUDON PHARMA (Private Limited) - Sint-Lambrechts-Woluwe

Dossier MEUDON PHARMA, printed on 3 November 2026 from databakkes.be/en/0636880026/meudon-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MEUDON PHARMA from Sint-Lambrechts-Woluwe, company number BE0636880026, closed financial year 2025 with a result of € 5,593 after tax. For that financial year MEUDON PHARMA recorded a gross margin of € 282,475 and equity of € 218,833. Compared with financial year 2024, the result moved from € 49,018 to € 5,593. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.

What it is worth Healthy

€ 218,833

▼ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 5,593

▼ 89% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 64,159

▲ 11% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 19,250 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.7

▲ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 160,235

▲ 33% vs 2024

€ 59,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 73,675

▲ 53% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 150,528

▼ 12% vs 2024

€ 28,558 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 71,676

▼ 1% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 33,223

▲ 29% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 252,533 Gross margin 2022: € 252,533 First fiscal year in the series	€ 269,717 Gross margin 2023: € 269,717 ▲ 7% vs 2022 (€ 252,533) Favourable step	€ 298,126 Gross margin 2024: € 298,126 ▲ 11% vs 2023 (€ 269,717) Favourable step	€ 282,475 Gross margin 2025: € 282,475 ▼ 5% vs 2024 (€ 298,126) Unfavourable step	▼ 5%
Profit after taxes	€ 19,623 Profit after taxes 2022: € 19,623 First fiscal year in the series	€ 47,886 Profit after taxes 2023: € 47,886 ▲ 144% vs 2022 (€ 19,623) Favourable step	€ 49,018 Profit after taxes 2024: € 49,018 ▲ 2% vs 2023 (€ 47,886) Favourable step	€ 5,593 Profit after taxes 2025: € 5,593 ▼ 89% vs 2024 (€ 49,018) Unfavourable step	▼ 89%
Equity	€ 171,666 Equity 2022: € 171,666 First fiscal year in the series	€ 212,052 Equity 2023: € 212,052 ▲ 24% vs 2022 (€ 171,666) Favourable step	€ 232,490 Equity 2024: € 232,490 ▲ 10% vs 2023 (€ 212,052) Favourable step	€ 218,833 Equity 2025: € 218,833 ▼ 6% vs 2024 (€ 232,490) Unfavourable step	▼ 6%
Total debts	€ 386,859 Total debts 2022: € 386,859 First fiscal year in the series	€ 323,298 Total debts 2023: € 323,298 ▼ 16% vs 2022 (€ 386,859) Favourable step	€ 306,958 Total debts 2024: € 306,958 ▼ 5% vs 2023 (€ 323,298) Favourable step	€ 290,066 Total debts 2025: € 290,066 ▼ 6% vs 2024 (€ 306,958) Favourable step	▼ 6%
Cash	€ 50,113 Cash 2022: € 50,113 First fiscal year in the series	€ 41,857 Cash 2023: € 41,857 ▼ 16% vs 2022 (€ 50,113) Unfavourable step	€ 57,760 Cash 2024: € 57,760 ▲ 38% vs 2023 (€ 41,857) Favourable step	€ 64,159 Cash 2025: € 64,159 ▲ 11% vs 2024 (€ 57,760) Favourable step	▲ 11%
Retained profit	€ 96,666 Retained profit 2022: € 96,666 First fiscal year in the series	€ 137,052 Retained profit 2023: € 137,052 ▲ 42% vs 2022 (€ 96,666) Favourable step	€ 157,490 Retained profit 2024: € 157,490 ▲ 15% vs 2023 (€ 137,052) Favourable step	€ 143,833 Retained profit 2025: € 143,833 ▼ 9% vs 2024 (€ 157,490) Unfavourable step	▼ 9%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 7,500 Dividend 2023: € 7,500 Unchanged (€ 0) Unchanged	€ 28,580 Dividend 2024: € 28,580 ▲ 281% vs 2023 (€ 7,500) Unchanged	€ 19,250 Dividend 2025: € 19,250 ▼ 33% vs 2024 (€ 28,580) Unchanged	▼ 33%
Bank debt	€ 267,153 Bank debt 2022: € 267,153 First fiscal year in the series	€ 200,907 Bank debt 2023: € 200,907 ▼ 25% vs 2022 (€ 267,153) Favourable step	€ 170,545 Bank debt 2024: € 170,545 ▼ 15% vs 2023 (€ 200,907) Favourable step	€ 150,528 Bank debt 2025: € 150,528 ▼ 12% vs 2024 (€ 170,545) Favourable step	▼ 12%
Balance sheet total	€ 558,526 Balance sheet total 2022: € 558,526 First fiscal year in the series	€ 535,350 Balance sheet total 2023: € 535,350 ▼ 4% vs 2022 (€ 558,526) Unchanged	€ 539,448 Balance sheet total 2024: € 539,448 ▲ 1% vs 2023 (€ 535,350) Unchanged	€ 508,899 Balance sheet total 2025: € 508,899 ▼ 6% vs 2024 (€ 539,448) Unchanged	▼ 6%
Employees (FTE)	2.5 Employees (FTE) 2022: 2.5 First fiscal year in the series	2 Employees (FTE) 2023: 2 ▼ 0.5 vs 2022 (2.5) Unchanged	2.2 Employees (FTE) 2024: 2.2 ▲ 0.2 vs 2023 (2) Unchanged	2.7 Employees (FTE) 2025: 2.7 ▲ 0.5 vs 2024 (2.2) Unchanged	▲ 0.5

Key figures of MEUDON PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEUDON PHARMA?

What happened at MEUDON PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 18, 2026 New annual accounts for financial year 2025: profit of € 5,593 (▼ 89% vs 2024). Source: NBB ↗
Sep 11, 2015 Incorporation, published in the Gazette. Source: Staatsblad ↗
Sep 9, 2015 New establishment in Sint-Lambrechts-Woluwe. KBO

In short

From € 19,623 profit in 2022 to € 5,593 profit in 2025.

Paid € 149,823 in corporate taxes since 2022.

Best year ever: 2024, with € 49,018 profit.

On average € 104,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Benoît MOUSSET Catherine BARVAIS

PHARMACIE MOUSSET

MEUDON PHARMA

Behind MEUDON PHARMA are Benoît MOUSSET and Catherine BARVAIS. The same people are also behind PHARMACIE MOUSSET.

Directors

According to the 2025 annual accounts

Benoît MOUSSET

Director

Also active at: PHARMACIE MOUSSET

Catherine BARVAIS

Director

Also active at: PHARMACIE MOUSSET

Establishments

Establishment units

Physical locations of this company

Registered office

Georges Henrilaan 180

1200 Sint-Lambrechts-Woluwe

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

11 September 2015 Source: Deed ↗

MOUSSET Benoît Gérard Jean(oprichter) 50%
BARVAIS Catherine Christiane Claire(oprichter) 50%

Details

Company number

0636.880.026

VAT number

BE 0636.880.026

Registered office

Georges Henrilaan 180, 1200 Sint-Lambrechts-Woluwe

Names & denominations

MEUDON PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 September 2015

Peppol

Active · Active since 18 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

MEUDON PHARMA

Financials

What happened to MEUDON PHARMA?

Management

Directors

Establishments

Establishment units

Shareholders according to the Official Gazette deeds

Details

Frequently asked questions